mRNA vaccines trigger immunity by delivering genetic instructions that host cells translate into a viral protein, which the immune system then recognizes and responds to. This approach leverages basic cell biology rather than introducing whole virus particles, allowing rapid design and manufacturing. Norbert Pardi at University of Pennsylvania and colleagues synthesized a comprehensive review explaining how nucleoside-modified mRNA in lipid nanoparticles directs this sequence of events and shapes immune outcomes. Katalin Karikó and Drew Weissman at University of Pennsylvania provided foundational evidence that chemical modification of mRNA reduces unwanted innate sensing, improving protein production and tolerability.
How mRNA is delivered and translated
Lipid nanoparticles serve as the delivery vehicle that protects the mRNA and helps it enter cells. Once an mRNA vaccine is injected, lipid nanoparticles fuse with cell membranes or are taken up by endocytosis, releasing the mRNA into the cell cytoplasm. There the cell’s ribosomes translate the mRNA into the encoded antigen protein, most commonly the viral spike protein used by SARS-CoV-2 vaccines. The produced protein can be presented directly on the cell surface via the major histocompatibility complex class I pathway, or processed and secreted for uptake by antigen-presenting cells and presentation on major histocompatibility complex class II molecules. This dual presentation provokes both cellular immunity and humoral immunity, meaning activation of CD8 positive T cells that can kill infected cells and B cells that produce antibodies.
Immune pathways activated and wider impacts
Activation begins with innate sensing of the vaccine components. Early work by Karikó and Weissman showed that including modified nucleosides in mRNA reduces detection by toll-like receptors and other innate sensors, which lowers excessive inflammation while allowing sufficient immune stimulation for effective adaptive responses. The lipid nanoparticle itself can provide an adjuvant effect by engaging innate pathways and recruiting antigen-presenting cells to the injection site. As described by Norbert Pardi at University of Pennsylvania and colleagues, the result is a coordinated response: helper CD4 positive T cells support B cell maturation and antibody production, while cytotoxic CD8 positive T cells identify and remove cells expressing the antigen.
Understanding these mechanisms explains both benefits and trade-offs. Rapid antigen production after vaccination contributes to swift development of protective antibody titers, a key factor in the vaccines’ accelerated development during the COVID-19 pandemic. At the same time, reactogenicity such as transient fever or soreness reflects innate immune activation and can vary with formulation or dosing. Logistical consequences also follow: lipid nanoparticle stability and cold-chain requirements influenced where and how vaccines could be distributed, shaping global access and equity. Cultural acceptance and trust in new technologies also affected uptake in different communities, underscoring that biological mechanisms operate within social and territorial contexts.
Clinical and lab studies by leading researchers at University of Pennsylvania and industry partners such as BioNTech demonstrate that mRNA platforms are adaptable to new targets, offering a flexible tool for emerging infectious diseases and potentially for cancer vaccines. Ongoing research continues to refine delivery, reduce side effects, and improve global access while monitoring long-term immune durability.